2,4-dihydroxy-3-propylbenzoic acid methyl ester | 79557-60-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-dihydroxy-3-propylbenzoic acid methyl ester
• 英文别名: methyl 2,4-dihydroxy-3-propylbenzoate
• CAS: 79557-60-1
• 化学式: C₁₁H₁₄O₄
• 分子量: 210.23
• InChiKey: WKUGLLRTMGGSPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,4-dihydroxy-3-propylbenzoic acid methyl ester 在 N-氯代丁二酰亚胺 作用下， 以 四氯化碳 、 水 为溶剂， 生成 5-chloro-2,4-dihydroxy-3-propylbenzoic acid methyl ester
  参考文献：
  名称：

  Catechol carboxylic acids

  摘要：

  这项发明涉及公式##STR1##的儿茶酚羧酸衍生物，其中，R.sub.1为##STR2##乙酰基，氢，羟基或烷酰氧基，R.sub.2为##STR3##羟基，氢或烷酰氧基，其中R为氢，低烷基或--(CH.sub.2).sub.n --N--(低烷基).sub.2，R.sub.3为氢，低烷基或氨基，R.sub.4为氢，低烷基，卤素或氨基，A为##STR4##其中，R.sub.5为氢或酰基，R.sub.6为氢，卤素，低烷基，芳基或环烷基，而R.sub.7和R.sub.8，独立地，为氢，低烷基或卤素，或A为##STR5##其中，R.sub.5为氢或酰基，R.sub.9为氢，低烷基，R.sub.10为氢，低烷基或卤素，R.sub.11为氢，低烷基，环烷基或卤素，m为0或1，n为2-10的整数，前提是R.sub.1或R.sub.2中不超过一个可以是羟基，烷酰氧基或##STR6##，当R为氢时，其与药学上可接受的碱盐，或当R为--(CH.sub.2).sub.n --N--(低烷基).sub.2时，其与药学上可接受的酸盐。公式I的化合物可用作治疗类风湿性关节炎、炎症性肠病如结肠炎、心血管疾病如心肌缺血、皮肤疾病如牛皮癣经局部给药治疗，以及支气管肺部疾病如哮喘的药物。

  公开号：

  US05025036A1
• 作为产物：
  描述：

  2,4-二羟基苯甲酸甲酯 在 镍 氢气 、 potassium carbonate 作用下， 以 乙酸乙酯 、 丁酮 为溶剂， 25.0~190.0 ℃ 、413.69 kPa 条件下， 反应 80.5h， 生成 2,4-dihydroxy-3-propylbenzoic acid methyl ester
  参考文献：
  名称：

  Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives

  摘要：

  A series of derivatives of 2,4-dihydroxy-3-propylacetophenone(1) were prepared and examined for their ability to block leukotriene D4 (LTD4) induced contraction of guinea pig ileum. Straight-chain carboxylic acids where the carboxyl group was separated from the acetophenone moiety by varying numbers of methylenes were evaluated, and maximum activity was obtained with the pentamethylene acid (6). Examination of ring substitution showed that the 2-propyl-3-hydroxy-4-acetyl substitution pattern was required for maximum LTD4 antagonist activity. Additional chain terminal groups were examined, and the acidic 5-tetrazolyl group separated from the acetophenone moiety by four to seven methylenes (26, 23, 27, 28) gave excellent in vitro and in vivo activities. Compound 26 (LY171883) had the best balance of in vitro and in vivo activity. It lacked bronchospastic activity at the doses administered and has been chosen for clinical evaluation.

  DOI：

  10.1021/jm00387a018

文献信息

• Dihydroxynaphthalene derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04937371A1

  公开（公告）日：1990-06-26

  There are described dihydroxy naphthalene derivatives of the formula ##STR1## in which R.sub.1 is hydrogen, lower alkyl or benzyl, R.sub.2 is hydrogen, hydroxy or lower alkanoyloxy, R.sub.3 is hydrogen or lower alkyl, R.sub.4 is hydrogen or halogen, R.sub.5 is hydrogen, acyl, methyl or benzyl, m is 0 or 1, and n is an integer from 2 to 10, as well as salts thereof with pharmaceutically acceptable bases when R.sub.1 is hydrogen. These compounds are useful as agents for the treatment of inflammatory bowel diseases, for instance, colitis, as pro-drugs, or as intermediates for the preparation of such compounds.

  描述了公式为##STR1##的二羟基萘衍生物，其中R.sub.1是氢、较低的烷基或苄基，R.sub.2是氢、羟基或较低的烷酰氧基，R.sub.3是氢或较低的烷基，R.sub.4是氢或卤素，R.sub.5是氢、酰基、甲基或苄基，m为0或1，n为2到10的整数，以及其与药学上可接受的碱的盐，当R.sub.1是氢时。这些化合物可用作治疗炎症性肠病的药物，例如结肠炎，作为前药，或作为制备这类化合物的中间体。
• [EN] HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS<br/>[FR] DERIVES HETEROCYCLIQUES UTILISES COMME AGENTS CONTRE LE DIABETE ET CONTRE L'OBESITE
  申请人：MERCK & CO., INC.

  公开号：WO1997028137A1

  公开（公告）日：1997-08-07

  (EN) The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.(FR) L'invention concerne des acétylphénols utiles comme composés contre l'obésité et contre le diabète. Sont également décrites des compositions et des méthodes d'utilisation de ces composés destinées au traitement du diabète et de l'obésité, servant à abaisser ou à moduler les taux de triglycérides et de cholestérol ou à élever les taux de lipoprotéines haute densité ou à accélérer le transit intestinal, ou à traiter l'athérosclérose.

  该发明涉及用作抗肥胖和抗糖尿病化合物的乙酰苯酚。还公开了用于治疗糖尿病和肥胖症的化合物的组合物和使用方法，用于降低或调节甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或增加肠道运动性或治疗动脉粥样硬化。
• Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes
  作者：Frederick J. Brown、Peter R. Bernstein、Laura A. Cronk、David L. Dosset、Kevin C. Hebbel、Thomas P. Maduskuie、Howard S. Shapiro、Edward P. Vacek、Ying K. Yee

  DOI：10.1021/jm00124a014

  日期：1989.4

  Considerations of the possible similarities between leukotriene D4 and its prototypical antagonist, FPL 55712, led to the development of a new series of leukotriene antagonists incorporating a hydroxyacetophenone group (e.g., the toluic acids 16 and 18). Although considerable attention has focused on FPL 55712-derived analogues, only limited investigations into alternatives for the standard 4-acetyl-3-hydroxy-2-propylphenoxy moiety have been reported. Therefore, an extensive study of modifications to the hydroxyacetophenone portion of toluic acid 18 was undertaken. Although no viable alternative to the 3-hydroxy moiety was discovered, replacements for the 2-propyl group (34, 37) and the 4-acetyl functionality (56, 59) yielded potent antagonists. A number of compounds exhibited longer duration of action in vivo than FPL 55712.
• Brown, Frederick J.; Bernstein, Peter R.; Cronk, Laura A., Journal of Medicinal Chemistry, 1989, vol. 32, # 4, p. 811 - 826
  作者：Brown, Frederick J.、Bernstein, Peter R.、Cronk, Laura A.、Dosset, David L.、Hebbel, Kevin C.、et al.

  DOI：——

  日期：——
• Synthesis and structure-activity relationships of benzophenones as inhibitors of cathepsin D
  作者：Celia A. Whitesitt、Richard L. Simon、Jon K. Reel、Sandra K. Sigmund、Michael L. Phillips、J. Kevin Shadle、Lawrence J. Heinz、Gary A. Koppel、David C. Hunden、Sherryl L. Lifer、Dennis Berry、Judy Ray、Sheila P Little、Xiadong Liu、Winston S. Marshall、Jill A. Panetta

  DOI：10.1016/0960-894x(96)00393-9

  日期：1996.9

  Non peptide inhibitors of cathepsin D, an aspartyl protease that has been implicated in many disease states including Alzheimer's disease, were prepared and evaluated. The most potent inhibitor of cathepsin D in this series was found to be (Z)-5-[[4-(4-benzoyl-3-hydroxy-2-propylphenoxy)methylphenyl]methylene]-2-thioxo-4-thiazolidinone (3f, IC50 = 210 nM). Copyright (C) 1996 Elsevier Science Ltd